HLA-DQ Gene Complementation and Other Histocompatibility Relationships in Man with the Anti-Ro/SSA Autoantibody Response of Systemic Lupus Erythematosus

Atsushi Fujisaku,† Mark Barton Frank,† Barbara Neas,‡ Morris Reichlin,∥ and John B. Harley††

†Arthritis and Immunology Program, Oklahoma Medical Research Foundation; ‡Department of Biostatistics and Epidemiology; and ∥Department of Medicine, University of Oklahoma Health Sciences Center; ††Veterans Administration Medical Center, Oklahoma City, Oklahoma 73104

Abstract

A strong gene interaction between HLA-DQ1 and DQ2 alleles has been associated with anti-Ro/SSA autoantibodies (Harley, J. B., M. Reichlin, F. C. Arnett, E. L. Alexander, W. B. Bias, and T. T. Provost. 1986. Science [Wash. DC]. 232:1145–1147; Harley, J. B., A. S. Sestak, L. G. Willis, S. M. Fu, J. A. Hansen, and M. Reichlin. 1989. Arthritis Rheum. 32:826–836; Hamilton, R. G., J. B. Harley, W. B. Bias, M. Roebber, M. Reichlin, M. C. Hochberg, and F. C. Arnett. 1988. Arthritis Rheum. 31:496–505). To test a gene complementation mechanism for these results, restriction fragment length polymorphisms (RFLP) of the DQα and DQβ genes have been related to Ro/SSA precipitins in patients with systemic lupus erythematosus. In this study Ro/SSA precipitins are related to the simultaneous presence of a particular pair of RFLPs. A DQα RFLP associated with HLA-DQ1 and a DQβ RFLP associated with HLA-DQ2 predict that the αβ heterodimer in HLA-DQ1/DQ2 heterozygotes is most closely related to anti-Ro/SSA autoantibodies, thereby supporting a gene complementation mechanism. Beyond this effect, an RFLP associated with HLA-DQ2 and/or DR7 is also related to Ro/SSA precipitins. Multiple molecular histocompatibility mechanisms are implicated, therefore, in the production of anti-Ro/SSA autoantibodies in autoimmune disease. For anti-Ro/SSA autoantibodies in SLE, and perhaps more generally, these data show that the histocompatibility antigens are among the elements that confer autoimmune response specificity and restrict the production of particular autoantibodies among patients with systemic lupus erythematosus. (J. Clin. Invest. 1990. 86:606–611.) Key words: autoimmunity • HLA-DQ • gene complementation • SLE • immune response genes

Introduction

For many immunogens the immune responsiveness found in F1 mice but in neither parental inbred mouse strain is the consequence of gene complementation of the class II histocompatibility molecules (1, 2). Though abundant evidence exists that analogous dimeric αβ molecules are present in man (3–5), examples of gene complementation demonstrating an in vivo human immune response are lacking. High titers of anti-Ro/SSA autoantibody predominate in HLA-DQ1/DQ2 heterozygous patients with primary Sjögren’s syndrome (6) and systemic lupus erythematosus (SLE) (7, 8). This gene interaction effect may also be an instance of possible gene complementation of the immune response genes which is examined at the gene level in this study.

Ro/SSA is an RNA-protein complex of unknown cellular function composed of a peptide complexed with one of four small uridine-rich RNAs which are transcribed by RNA polymerase III (9). In addition to the well known 60-kd Ro/SSA peptide (10–12), 52- and 54-kd peptides have been recently defined (13, 14). Available data also support binding of the 52 kD Ro/SSA peptide to the hY RNAs (13). Present evidence supports anti-Ro/SSA having an immunopathogenic role in congenital complete heart block as well as in some of the SLE and Sjögren’s syndrome patients who have nephritis, sialadenitis, photosensitive dermatitis, or vasculitis (15–22).

To better understand the gene interaction at HLA-DQ associated with anti-Ro/SSA antibodies, we have analyzed the relationship between restriction fragment length polymorphisms (RFLP) of the DQα and DQβ genes to HLA antigens and anti-Ro/SSA autoantibodies in SLE patients. Ro/SSA precipitins were found in nearly all SLE patients who had a particular pair of RFLPs. One is detected by a DQα probe and associated with HLA-DQ1 positive SLE patients and the other RFLP is detected by a DQβ probe in HLA-DQ2-positive patients. Moreover, this effect was stronger than any single allele whether defined by HLA serology or by RFLP analysis at HLA-DQ. Beyond this effect, however, a single RFLP was found to also be associated with Ro/SSA precipitins. These data not only show that gene complementation of HLA may be important in human immune responses, but also suggest that multiple molecular components of the normal immune apparatus determine the specificity of autoimmune responses.

Methods

Patients and anti-Ro/SSA antibody. Informed consent and peripheral blood was obtained from 26 patients who satisfied the 1982 revised American Rheumatism Association classification criteria for systemic lupus erythematosus (SLE) (23). Precipitating autoantibodies to Ro/SSA were detected by Ouchterlony immunodiffusion against bovine spleen extract (24) and by counterimmunoelectrophoresis against human tissue extract (25). In this study, all sera gave the same results in these two tests when examined for precipitating anti-Ro/SSA autoantibodies.

HLA typing. Lymphocytes were prepared from heparinized peripheral blood by Ficoll separation and the fraction enriched for B-lym-
phocytes was obtained with a nylon wool column. HLA-DQ and HLA-DR typing was performed with a complement-dependent microcyotoxic technique (26) using Terasaki HLA typing trays (One Lambda Inc., Los Angeles, CA).

Southern blot. Genomic DNA was extracted from patient peripheral leukocytes with proteinase K digestion and phenol extraction, and digested completely with Bam HI, Eco RI, Eco RV, Hind III, Pst I, Pvu II or Taq I under conditions recommended by the restriction enzyme manufacturers. RFLPs at DQ were detected by Southern blotting of restriction enzyme digested DNA followed by hybridization to 32P radiolabeled (27-29) DQα or DQβ gene probes (30, 31) on nylon membranes (Biotrace RT; Gelman Scientific, Inc., Ann Arbor, MI).

Data analysis. Comparison of categorical variables has been evaluated using the two-tailed Fisher's exact test unless otherwise indicated. The F statistic is presented to appraise the relation between anti-Ro/SSA and serologic or RFLP alleles and is taken from the analysis preliminary to the logistic regression procedure. Step-wise logistic regression analysis has been applied using the BMDP-LR program (32) with the presence of Ro/SSA precipitins as the dependent variable and selected RFLPs or serologic HLA-typing results as independent variables where step selections have been based upon the approximate asymptomatic covariance estimate. Briefly, the independent variable with the highest F (if F has P < 0.15) enters the model first. After recalculating the model, the effects of all independent variables are reassessed. Independent variables are entered if the F to enter has P < 0.15 or removed if the F to remove has P < 0.10 until none of the remaining independent variables pass the remove or enter limits.

Relevant serologic data were complete in 62 subjects and complete RFLP data were available from 67 subjects of the 76 SLE patients enrolled. 55 had both complete serologic and RFLP data. Each analysis was performed upon one of these overlapping cohorts.

Results and Discussion

Of the 62 patients with serologic HLA-typing of DQ1 and DQ2 alleles 15 of the 18 HLA-DQ1/DQ2 heterozygotes have a Ro/SSA precipitating antibody (P = 0.005 compared to 21 of the remaining 44 patients by two-tailed Fisher's exact test) consistent with previous reports in Sjögren's syndrome and SLE patients (6, 8). For the entire SLE cohort, no HLA antigen allele nor genotype at HLA-DR or HLA-DQ is as powerfully associated with anti-Ro/SSA as is the HLA-DQ1/DQ2 heterozygous state.

70 RFLPs were identified in this population of SLE patients with seven restriction endonucleases (Bam HI, Eco RI, Eco RV, Hind III, Pst I, Pvu II, and Taq I); 46 with the DQβ probe and 24 with the DQα probe. Since 83% of the HLA-DQ1/DQ2 heterozygotes were Ro/SSA precipitin positive, combinations of RFLPs that represented combinations of HLA-DQ1 and HLA-DQ2 alleles were considered in the initial analysis. The RFLPs were divided into four groups based upon their association with HLA-DQ1 or HLA-DQ2 (P < 0.005 by two-tailed Fisher's exact test) and whether they were detected by the DQα or DQβ gene probe (Table I). The DQ1α group is composed of four RFLPs detected by the DQα probe and associated with HLA-DQ1: Hind III 7.6 kb, Pst I 16.0 kb, Pvu II 4.8 kb, and Eco RI 16.0 kb. The DQ2α group has only the Pvu II 2.8 kb RFLP. The DQ1β group contains five RFLPs: Pst I 13.0 kb, Bam HI 3.0 kb, Pvu II 2.2 kb, Eco RI 2.2 kb, and Eco RV 4.9 kb. Finally, the DQ2β group also contains five RFLPs: Bam HI 4.2 kb, Hind III 13.0 kb, Pst I 5.5 kb, Pvu II 1.7 kb, and Pvu II 2.4 kb. The RFLP of each group most closely associated with the presence of a Ro/SSA precipitin was selected as a representative for subsequent analysis. Since the DQ1α and DQ2β RFLPs together were the most closely related to the HLA-DQ1/DQ2 heterozygotes (Table I), this pair was predicted to be more closely associated with the presence of Ro/SSA precipitins than any other combination of HLA-DQ1 and DQ2 RFLPs. The RFLP data from 67 SLE patients were used to test this hypothesis by stepwise logistic regression (32). The four possible pairwise combinations related to HLA-DQ1 and DQ2 of the four RFLP groups (DQ1α and DQ2α, DQ1α and DQ2β, DQ1β and DQ2α, and DQ1β and DQ2β) were evaluated for their possible contribution to anti-Ro/SSA (Table II). Only the DQ1α and DQ2β RFLP combination represented by the Pvu II 4.8 kb (DQα) and Pvu II 1.7 kb (DQβ) was incorporated into

Table I. RFLPs Detected by DQα or DQβ Gene Probes Associated with HLA-DQ1 or HLA-DQ2

<table>
<thead>
<tr>
<th>Probe</th>
<th>Restriction enzyme</th>
<th>DNA fragment (kb)</th>
<th>HLA-DQ1 (P)</th>
<th>HLA-DQ2 (P)</th>
<th>HLA-DQ1/DQ2 (P)</th>
<th>Anti-Ro/SSA (P)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DQ1α RFLP (HLA-DQ1 associated RFLP with DQα probe)</td>
<td>Pvu II</td>
<td>4.8</td>
<td>&lt; 10−7</td>
<td>0.04*</td>
<td>0.04</td>
<td>0.22</td>
</tr>
<tr>
<td>DQ1β RFLP (HLA-DQ1 associated RFLP with DQβ probe)</td>
<td>Bam HI</td>
<td>3.0</td>
<td>0.001</td>
<td>0.18*</td>
<td>0.25</td>
<td>0.27</td>
</tr>
<tr>
<td>DQ2α RFLP (HLA-DQ2 associated RFLP with DQα probe)</td>
<td>Pvu II</td>
<td>2.8</td>
<td>0.15</td>
<td>0.005</td>
<td>0.15</td>
<td>1.0</td>
</tr>
<tr>
<td>DQ2β RFLP (HLA-DQ2 associated RFLP with DQβ probe)</td>
<td>Pvu II</td>
<td>1.7</td>
<td>0.38*</td>
<td>&lt; 10−5</td>
<td>0.007</td>
<td>0.01</td>
</tr>
</tbody>
</table>

Associations of RFLPs with the serologically defined alleles HLA-DQ1, HLA-DQ2 and HLA-DQ1/DQ2 heterozygotes as well as with anti-Ro/SSA from 55 SLE patients are presented as P values from a two-tailed Fisher's exact test. Only RFLPs associated with HLA-DQ1 or HLA-DQ2 at P < 0.005 are considered. One representative of each RFLP group is presented. * Negative associations (odds ratio < 1.0).
Table II. A RFLP Combination at HLA-DQ Associated with Ro/SSA Precipitins and Predicting a Gene Complementation Effect

<table>
<thead>
<tr>
<th>Step</th>
<th>Term in model</th>
<th>df*</th>
<th>$x^2$</th>
<th>$P$</th>
<th>Coefficient ±</th>
<th>Improvement</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>DQ1α and DQ2β</td>
<td>1</td>
<td>13.3</td>
<td>&lt; 0.005</td>
<td>3.1 ± 1.1</td>
<td></td>
</tr>
</tbody>
</table>

Stepwise logistic regression model of anti-Ro/SSA in HLA-typed SLE patients was predicted by combinations of the RFLP groups defined by association with HLA-DQ1 or HLA-DQ2 alleles and by hybridization to the DQα or DQβ cDNA probes. These included the representative RFLPs presented in Table I in the following combinations: DQ1α and DQ2α, DQ1α and DQ2β, DQ1β and DQ2α, and DQ1β and DQ2β. Complete data for these analyses were available in 67 patients. Pvu II 4.8 kb and Pvu II 1.7 kb, representing the DQ1α and DQ2β RFLP groups was the only DQ1- and DQ2-associated RFLP combination incorporated into the model. The associated RFLPs within each group were then substituted for the representative RFLPs and tested in all combinations by logistic regression along with this RFLP pair. In each case the Pvu II 4.8-kb and 1.7-kb pair was the RFLP pair most closely related to the presence of Ro/SSA precipitins.

* Degrees of freedom.
\( \text{df} \) Coefficient ± standard error.

the model (Table II). The remaining capacity of the other three RFLP combinations to change the model was quite small ($P \geq 0.2$). The gene interaction effect at HLA-DQ observed in serologic typing data, therefore, was explained by the DQ1α and DQ2β RFLP combination.

Gene complementation requires complementing effects derived from each of two different genetic loci. These data fulfill this requirement. To satisfy the hypothesis that the anti-Ro/SSA response is at least partially restricted by the presence of a particular αβ heterodimer molecule of HLA-DQ would require that one parental chromosome code for the DQα peptide while the other code for DQβ. That these data define such an outcome and that both DQα and DQβ peptides are commonly polymorphic (33) is consistent with the formation of a particular αβ DQ heterodimer as a molecular explanation for the observed gene complementation associated with anti-Ro/SSA production in these SLE patients. In recent data obtained by transfecting homozygous cell lines with different DQβ alleles, the DQ1α/DQ2β heterodimer molecule was not found (34). The significance of these observations for the interpretation of the detailed molecular mechanism of gene complementation for the generation of anti-Ro/SSA in these patients must await the direct evaluation for the presence of the hypothesized molecule in SLE patients.

While the HLA-DQ1/DQ2 heterozygotes show a strong association with anti-Ro/SSA neither HLA-DQ1 nor HLA-DQ2 alone are associated with anti-Ro/SSA (Table III). Of the RFLPs representative of HLA-DQ1 and HLA-DQ2, only the DQ2β RFLP is associated with anti-Ro/SSA. (The data presented in Table III for the Eco RV 20-kb RFLP detected by the DQβ probe is discussed below.) While there may be some racial difference in the relationships of particular RFLPs to anti-Ro/SSA, individuals with both the DQ1α and DQ2β RFLPs are associated with anti-Ro/SSA in both blacks and whites. Moreover, in the entire SLE cohort those with DQ1α and DQ2β define the group most closely associated with anti-Ro/SSA. Nearly half (49%) of the anti-Ro/SSA precipitin posi-

Table III. Associations of Anti-Ro/SSA with HLA-DQ1 and DQ2 Serologic Alleles and RFLPs in SLE*

<table>
<thead>
<tr>
<th>Allele</th>
<th>DQ1</th>
<th>DQ2</th>
<th>DQ1/DQ2</th>
<th>DQ1α</th>
<th>DQ1β</th>
<th>DQ2α</th>
<th>DQ2β</th>
<th>DQ1α/DQ2β</th>
<th>EcoRV20</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>42</td>
<td>31</td>
<td>18</td>
<td>48</td>
<td>29</td>
<td>53</td>
<td>32</td>
<td>20</td>
<td>11</td>
</tr>
<tr>
<td>All</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>present</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>aRo</td>
<td>28</td>
<td>21</td>
<td>15</td>
<td>27</td>
<td>17</td>
<td>29</td>
<td>23</td>
<td>17</td>
<td>10</td>
</tr>
<tr>
<td>aRo with allele</td>
<td>8</td>
<td>15</td>
<td>21</td>
<td>8</td>
<td>18</td>
<td>6</td>
<td>12</td>
<td>18</td>
<td>25</td>
</tr>
<tr>
<td>aRo without allele</td>
<td>2.07</td>
<td>2.40</td>
<td>7.21</td>
<td>1.08</td>
<td>0.82</td>
<td>0.61</td>
<td>10.7</td>
<td>14.6</td>
<td>8.67</td>
</tr>
<tr>
<td>1.54</td>
<td>0.30</td>
<td>0.010</td>
<td>0.30</td>
<td>0.37</td>
<td>0.44</td>
<td>0.0017</td>
<td>0.0003</td>
<td>0.0045</td>
<td></td>
</tr>
<tr>
<td>F statistic</td>
<td>0.16</td>
<td>0.13</td>
<td>0.010</td>
<td>0.30</td>
<td>0.37</td>
<td>0.44</td>
<td>0.0017</td>
<td>0.0003</td>
<td>0.0045</td>
</tr>
<tr>
<td>P value</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>n = 22</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>present</td>
<td>15</td>
<td>11</td>
<td>8</td>
<td>17</td>
<td>8</td>
<td>17</td>
<td>10</td>
<td>7</td>
<td>8</td>
</tr>
<tr>
<td>aRo with allele</td>
<td>12</td>
<td>10</td>
<td>8</td>
<td>12</td>
<td>6</td>
<td>14</td>
<td>10</td>
<td>7</td>
<td>8</td>
</tr>
<tr>
<td>aRo without allele</td>
<td>4</td>
<td>6</td>
<td>8</td>
<td>4</td>
<td>10</td>
<td>2</td>
<td>6</td>
<td>9</td>
<td>8</td>
</tr>
<tr>
<td>F statistic</td>
<td>0.62</td>
<td>4.0</td>
<td>5.45</td>
<td>0.03</td>
<td>0.16</td>
<td>5.88</td>
<td>10.6</td>
<td>4.97</td>
<td>6.39</td>
</tr>
<tr>
<td>P value</td>
<td>0.44</td>
<td>0.059</td>
<td>0.030</td>
<td>0.86</td>
<td>0.70</td>
<td>0.024</td>
<td>0.0037</td>
<td>0.037</td>
<td>0.020</td>
</tr>
<tr>
<td>White</td>
<td>n = 38</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>present</td>
<td>26</td>
<td>20</td>
<td>10</td>
<td>30</td>
<td>21</td>
<td>34</td>
<td>21</td>
<td>12</td>
<td>3</td>
</tr>
<tr>
<td>aRo with allele</td>
<td>15</td>
<td>11</td>
<td>7</td>
<td>14</td>
<td>11</td>
<td>14</td>
<td>13</td>
<td>9</td>
<td>2</td>
</tr>
<tr>
<td>aRo without allele</td>
<td>4</td>
<td>8</td>
<td>12</td>
<td>4</td>
<td>7</td>
<td>4</td>
<td>5</td>
<td>9</td>
<td>16</td>
</tr>
<tr>
<td>F statistic</td>
<td>1.95</td>
<td>0.40</td>
<td>2.18</td>
<td>0.60</td>
<td>1.54</td>
<td>0.20</td>
<td>3.64</td>
<td>8.12</td>
<td>0.73</td>
</tr>
<tr>
<td>P value</td>
<td>0.17</td>
<td>0.53</td>
<td>0.15</td>
<td>0.44</td>
<td>0.22</td>
<td>0.66</td>
<td>0.064</td>
<td>0.0069</td>
<td>0.40</td>
</tr>
</tbody>
</table>

* Alleles are defined by serologic reactivity or as RFLPs which are largely defined in Table I. Eco RV20 is the 20-kb fragment detected by the DQβ probe after digestion with the Eco RV restriction endonuclease. Only patients with complete serologic data (n = 62) or with RFLP data complete for the alleles presented (n = 67) are considered. The number of patients in each category is presented. One American Indian and a Chinese patient are included in the total group. The F statistic presented compares the likelihood of anti-Ro/SSA being found with as opposed to without the allele and for all SLE patients is used in the initial simple statistics of the logistic regression analyses presented in Tables II and IV. P values from the F statistic are not corrected for multiple comparisons. Anti-Ro/SSA is abbreviated to aRo.

808 A. Fujii, M. R. Frank, B. Neas, M. Reichlin, and J. B. Harley
tive patients have the DQ1α and DQ2β RFLP combination (from Table III, odds ratio = 9.1, 95% confidence interval 4.6 to 18.3, sensitivity = 0.49, specificity = 0.91, and predictive value = 0.85).

Other effects between RFLPs and anti-Ro/SSA may also be present and they may be as important as or more important than the DQ1α and DQ2β RFLP combination in other cohorts of SLE patients. To detect such additional effects in this sample of SLE patients, model building with stepwise logistic regression has been continued by including all RFLPs associated with Ro/SSA precipitins as potential independent variables along with the DQ1α and DQ2β RFLP combination. Associations of individual RFLPs with anti-Ro/SSA have been found only with the DQ8 gene probe. They include an Eco RV 20.0 kb fragment (P = 0.002) as well as two RFLPs of the DQ2β RFLP group, Pvu II 1.7 kb and Bam HI 4.2 kb (P < 0.003). These RFLPs, along with three other RFLPs less closely associated with Ro/SSA precipitins, have been evaluated individually and together along with the DQ1α and DQ2β RFLP combination in stepwise logistic regression models of anti-Ro/SSA. The DQ1α and DQ2β RFLP combination has always made the greatest contribution to each model and is consistently incorporated first (Table IV). Subsequently, only the Eco RV 20.0 kb RFLP detected with the DQ8 probe is incorporated into the model. The Eco RV 20.0 kb RFLP is associated with HLA-DR7 in these SLE patients (P < 0.003) nearly all of whom are HLA-DQ2 positive as has been found in normal donors by others (35–37). This RFLP did not hybridize to a DR5 gene probe (38) and therefore does not reflect variation at HLA-DR. Unlike the HLA-DQ1/DQ2 effect (Table II) no RFLP detected with DQ8s was preferentially associated with the DQ8 Eco RV 20-kb fragment in Ro/SSA precipitin positive SLE patients (analysis is not presented). The DQ1α and DQ2β RFLP combination or the DQ8 Eco RV 20.0-kb RFLP is associated with 21 of the 35 (60%) Ro/SSA precipitin positive SLE patients, while only 3 of the 32 (9%) Ro/SSA precipitin negative patients had either (odds ratio 14.5, 95% confidence interval 3.3 to 55).

The distribution of HLA alleles in human populations as well as the linkage disequilibrium found between alleles at different HLA loci are known to vary between ethnic groups. For example, the HLA-B8 and HLA-DR3 are found together in North American whites more frequently than expected and with other associated alleles constitute a haplotype not ordinarily found in other ethnic groups (35). As noted above a third of the SLE patients in this cohort are black and two-thirds are white (Table III). The frequencies of the HLA-DQ1 and DQ2 serologic alleles as well as the DQ1 or DQ2 associated RFLPs (Table I) are very similar in both the white and black SLE patients of this study. The Eco RV 20-kb RFLP, however, is an example of a genetic marker more commonly found in the black patients in this study than in the whites (P < 0.02). A larger relative contribution to the association of Ro/SSA precipitins with either the Eco RV 20.0 kb RFLP or the HLA-DR7 serologically defined allele is derived from the black SLE patients. Both racial groups appear to contribute to the association of Eco RV 20.0 kb with Ro/SSA precipitins as presented in the final model (Table IV). A previous study has found Ro/SSA precipitins to be primarily related to HLA-DR7 in black patients with SLE (39). The Eco RV 20-kb RFLP reported here may be a molecular marker for this serologic allele in such patients. In the white patients the DQ1α/DQ2β RFLP combination was closely related to anti-Ro/SSA precipitins while the Eco RV 20.0 kb DQ8 fragment made virtually no additional contribution.

The data and analysis of these SLE patients suggest additional observations concerning previous work. First, linkage disequilibrium between HLA-DR3 and HLA-DQ2 as well as HLA-DR2 and HLA-DQ1 means that at least a component of the association of HLA-DR3 and HLA-DR2 with anti-Ro/SSA (2, 3, 40–45) may be reflected by the gene products related to DQ1α and DQ2β in combination. Second, the multiplicity and complexity of the histocompatibility relationships may cause these or other histocompatibility mechanisms to predominate in particular cohorts of patients. In this cohort, both the Eco RV 20-kb RFLP and the DQ1α and DQ2β RFLP combination require an allele associated with HLA-DQ2. This is consistent with the DQβ RFLPs of HLA-DQ2 being strongly associated with anti-Ro/SSA. Third, the presence of two histocompatibility antigens related to an autoantibody in SLE is consistent with the proposed model for clinical heterogeneity of SLE where once the individual expresses the now unknown fundamental immune defect of SLE, the particular autoantibodies produced are determined at least in part by histocompatibility composition (7). Fourth, since the anti-Ro/SSA precipitin results were identical in this group of SLE patients with bovine and human Ro/SSA antigen sources, the recently appreciated species variation in the Ro/SSA antigen does not influence these results (46). The complexity of the Ro/SSA immune response as reflected by the multiple Ro/SSA peptides suggests that additional levels of immune discrimination will be found with the analysis of more restricted antigenic specificities of the Ro/SSA antigenic particle.

There is good evidence for the DQ1α and DQ2β RFLPs reflecting allelic variants at HLA-DQ. First, each is strongly associated in this SLE patient group with an HLA-DQ serologically defined allele. Second, there is no evidence of cross-hybridization to HLA-DR with any DQ2β group RFLP since a DRβ probe (38) failed to hybridize to any DQ2β RFLPs. Third, both RFLPs from the DQ1α and DQ2β groups are most closely associated with DQ alleles in other studies (36, 37, 47).

Further, the data support another allele at the DRβ or the DQ8 locus which is associated with the HLA-DQ2, DR7 haplotype being related to Ro/SSA precipitins. These results support the existence of multiple class II molecular mechanisms.

Table IV. Final Logistic Regression Model of the Contribution of HLA-DQ RFLPs to anti-Ro/SSA in SLE

<table>
<thead>
<tr>
<th>Step</th>
<th>Term in final model</th>
<th>df*</th>
<th>( \chi^2 )</th>
<th>( p )</th>
<th>Coefficient ( \beta )</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>DQ1α and DQ2β</td>
<td>1</td>
<td>13.3</td>
<td>&lt; 0.0005</td>
<td>2.0 ± 0.70</td>
</tr>
<tr>
<td>2</td>
<td>Eco RV 20.0 kb (DQ8)</td>
<td>1</td>
<td>4.7</td>
<td>0.030</td>
<td>2.1 ± 1.1</td>
</tr>
</tbody>
</table>

Stepwise logistic regression analysis of the RFLPs contributing to anti-Ro/SSA has been performed in 67 SLE patients. DQ1α and DQ2β indicate the respective RFLPs, Pvu II 4.8 kb and Pvu II 1.7 kb, identified in Table II. DQ8 RFLPs independently associated with anti-Ro/SSA in these SLE patients (P < 0.05) have also been tested for inclusion in this model including Bam HI 4.2 kb, Taq I 7.0 kb, Hind III 15.0 kb, Pst I 5.5 kb, Pvu II 1.7 kb, Eco RV 20.0 kb.

* Degrees of freedom.

\( \beta \) Coefficient ± standard error.

HLA-DQ Gene Complementation with Anti-Ro/SSA in Systemic Lupus Erythematosus 609
for the anti-Ro/SSA autoimmune response in SLE. One is likely to involve an αβ heterodimer gene complementation product of the HLA-DQ locus, while in a second a class II β peptide gene product at HLA-DR7 or HLA-DQ2 is important. Moreover, these histocompatibility alleles must serve as restriction elements for the autoimmune response in SLE. Hence, some of the variation in autoimmune response between SLE patients may be attributed to differences in histocompatibility composition, thereby demonstrating an important analogy to the immune response against ordinary, non-autoimmune antigens. The conclusion follows that the autoimmune response in the example of anti-Ro/SSA in SLE is dependent upon an antigen and is not the result of autonomous B lymphocyte activation. These data define some of the normal molecular machinery of the immune response used in generating an autoimmune antibody response.

Acknowledgments

We are grateful to Ms. Kathy Hardgrave for technical assistance, to Dr. Bo Dupont for sharing an unpublished manuscript and to Dr. J. Donald Capra for providing cDNA probes.

This work has been supported by U.S. Public Health Service grants (AI-24717, AR-39577, AR-31133, AI-21568, AR-322214), the March of Dimes Birth Defects Foundation (1-1109), the Lupus Foundation of America, the Oklahoma Lupus Association, Inc., and the Oklahoma Health Research Program. Dr. Frank is an Alumni Research Scholar of the University of Oklahoma College of Medicine.

References